In re Marden, Patent Appeal No. 2632.
Decision Date | 25 March 1931 |
Docket Number | Patent Appeal No. 2632. |
Citation | 47 F.2d 958 |
Parties | In re MARDEN et al. |
Court | U.S. Court of Customs and Patent Appeals (CCPA) |
Max F. Reges, of Bloomfield, N. J. (Raymond Jones, of Washington, D. C., of counsel), for appellants.
T. A. Hostetler, of Washington, D. C. (Howard S. Miller, of Washington, D. C., of counsel), for Commissioner of Patents.
Before GRAHAM, Presiding Judge, and BLAND, HATFIELD, GARRETT, and LENROOT, Associate Judges.
From a decision of the Board of Appeals of the United States Patent Office, affirming the decision of the Examiner, refusing to allow claims 9 to 12, inclusive, and 14 to 19, inclusive, on the ground that the claims defined nothing inventive over the prior art, the applicants have appealed here. Claims 9 to 12 are for a method of producing ductile vanadium, and claim 9 is regarded as illustrative of the method claims. Claims 14, 15, 16, 17, 18, and 19 are article claims and these with claim 9 are as follows:
The process claims relate to a process for preparing vanadium so that it will be ductile. The metal in its ductile state may be made into filaments for use in various electrical arts. The process consists of taking oxide of vanadium and reducing the same to a form of vanadium powder. This is slowly heat treated in a high vacuum until substantially all the adsorbed and absorbed gases are removed. The powder is then fused to remove any hydrogen remaining. A filament may then be formed by cold working the fused body of vanadium.
It is contended by appellants that they were the first to produce ductile vanadium and that they are not only entitled to all of their process claims but that they are entitled to a patent on the article, ductile vanadium, in its various forms.
It is conceded by counsel on both sides that ductile or malleable vanadium is nothing more or less than vanadium freed from all of its impurities and that all pure vanadium is ductile.
The Board of Appeals allowed certain method claims relating to the method of producing the substantially pure metal powder and rejected the method claims at issue relating to the vacuum heat-treating process, on the references Kuzel et al., 1,088,909, March 3, 1914, and Liebmann, 1,111,698, September 22, 1914, and also referred to the patent to Von Bolton, 799,441, September 12, 1905. In the decision of the Board of Appeals the following language is used:
...
To continue reading
Request your trial-
Ass'n For Molecular Pathology v. United States Patent
...45 subsequently relied on General Electric in rejecting patents claiming purified uranium and vanadium. See In re Marden, 18 C.C.P.A. 1046, 47 F.2d 957, 957-58 (1931) (“ Marden I ”); In re Marden, 18 C.C.P.A. 1057, 47 F.2d 958, 959 (1931) (“ Marden II ”) (“The quality of purity of vanadium ......
-
The Ass'n For Molecular Pathology v. United States Patent
...cases are similarly inapposite,7 directed as they are to the patent ineligibility of purified natural elements—ductile uranium, 18 CCPA 1046, 47 F.2d 957 (1931), and vanadium, 18 CCPA 1057, 47 F.2d 958 (1931)—that are inherently ductile in purified form. Parke–Davis and Marden address a sit......
-
Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office
...cases are similarly inapposite, directed as they are to the patent ineligibility of purified natural elements—ductile uranium, 18 CCPA 1046, 47 F.2d 957 (1931), and vanadium, 18 CCPA 1057, 47 F.2d 958 (1931)—that are inherently ductile in purified form. While purified natural products thus ......
-
Merck & Co. v. Olin Mathieson Chemical Corporation
...U.S. 127, 68 S.Ct. 440, 92 L.Ed. 588 (a composite culture of noninhibitive strains of different, but known, species of bacteria); In re Marden, 47 F.2d 957, 18 C.C.P.A., Patents, 1046 (uranium); In re Marden, 47 F.2d 958, 18 C.C.P.A., Patents, 1057 (ductile vanadium); General Electric Co. v......
-
New York intellectual property law review.
...2010). (231) Ass'n for Molecular Pathology, 653 F.3d at 1342. (232) Id. at 1352. (233) Id. (234) See id. (235) Id. (citing In re Marden, 47 F.2d 958, 959 (C.C.P.A. 1931)). But see Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. (236) Ass'n for Molecular Pathology, 6......